Adaptation of contingency management for stimulant use disorder during the COVID-19 pandemic

J Subst Abuse Treat. 2020 Nov:118:108102. doi: 10.1016/j.jsat.2020.108102. Epub 2020 Aug 11.

Abstract

The current coronavirus disease (COVID-19) pandemic has rapidly spread across the world. Individuals with stimulant use disorder are a vulnerable population, who are particularly at risk of negative outcomes during this pandemic due to several risk factors, including mental and physical comorbidities, weakened immune responses, high-risk behaviors, and barriers to healthcare access. Engaging patients with stimulant use disorder in regular treatment has become even more difficult during this pandemic, which has resulted in many cuts to addiction treatment programs. The most effective treatment options for stimulant use disorder are psychosocial interventions, which rely heavily on in-person interactions, posing an added challenge during physical distancing. In particular, contingency management (CM) is a behavioral therapy that utilizes tangible reinforcements to incentivize targeted behavior changes, and is an effective treatment intervention used for stimulant use disorder. This paper highlights the treatment challenges for individuals with stimulant use disorder and the importance of adapting CM programs during COVID-19. We present strategies for how CM can be adapted and its role expanded in a safe way during the COVID-19 pandemic to help prevent infection spread, stimulant use relapse, and worsened psychosocial consequences.

Keywords: Amphetamine; COVID-19; Cocaine; Contingency management; Stimulant.

MeSH terms

  • Behavior Therapy / methods*
  • COVID-19
  • Central Nervous System Stimulants / administration & dosage
  • Central Nervous System Stimulants / adverse effects
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / prevention & control
  • Humans
  • Pandemics / prevention & control
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / prevention & control
  • Risk Factors
  • Substance-Related Disorders / epidemiology
  • Substance-Related Disorders / therapy*
  • Vulnerable Populations

Substances

  • Central Nervous System Stimulants